GNPX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of -255.85%. Genprex, Inc.'s return on equity of -900.4% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 12698.64%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.49%. Given that Genprex, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Genprex, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Genprex, Inc. has a beta of -0.810, which suggesting that the stock is 180.953% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Genprex, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Genprex, Inc.'s net income of -$3.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus 10.65x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of --. Genprex, Inc.'s return on equity of -900.4% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 12698.64%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $45.30 which suggests that it could grow by 71.46%. Given that Genprex, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Genprex, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Genprex, Inc. has a beta of -0.810, which suggesting that the stock is 180.953% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.919, suggesting its more volatile than the S&P 500 by 91.942%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Genprex, Inc.'s net income of -$3.8M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Genprex, Inc.'s net margin of --. Genprex, Inc.'s return on equity of -900.4% beat Palatin Technologies's return on equity of --.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 12698.64%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Genprex, Inc. has higher upside potential than Palatin Technologies, analysts believe Genprex, Inc. is more attractive than Palatin Technologies.

Genprex, Inc. has a beta of -0.810, which suggesting that the stock is 180.953% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Genprex, Inc.'s net income of -$3.8M is higher than Palatin Technologies's net income of --. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Genprex, Inc.'s net margin of --. Genprex, Inc.'s return on equity of -900.4% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Genprex, Inc. has a consensus price target of $7.50, signalling upside risk potential of 12698.64%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3283.28%. Given that Genprex, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Genprex, Inc. is more attractive than Theriva Biologics, Inc..

Genprex, Inc. has a beta of -0.810, which suggesting that the stock is 180.953% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Genprex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genprex, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Genprex, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Genprex, Inc.'s net income of -$3.8M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Genprex, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genprex, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.